Austin, Texas, United States, August 13th, 2026, NewsDirect
This article has been disseminated on behalf of Quantum BioPharma Ltd. and may include paid advertising.
- Researchers recognize that a large share of long-term disability accumulates independent of relapses altogether, a phenomenon researchers call progression independent of relapse activity.
- That shift has forced researchers to look at what is actually driving PIRA. A major suspect is chronic active lesions, sometimes called smoldering or mixed active-inactive lesions.
- Rather than broadly suppressing the immune system, Quantum BioPharma’s Lucid-MS is designed to inhibit myelin degradation, preserve myelin and support functional recovery.
Multiple sclerosis is quietly shifting how drugmakers define success. Instead of judging a therapy mainly by whether it reduces relapses, developers are chasing the slower, harder-to-treat processes that drive long-term disability, and Quantum BioPharma (NASDAQ: QNTM) (CSE: QNTM) is one of the companies building a therapy around that shift, through its myelin-focused candidate Lucid-MS.
For decades, MS treatment success was measured largely by relapse rates. Fewer flare-ups meant a drug was working. But researchers now recognize that a substantial proportion of long-term disability accumulates independent of…
NOTE TO INVESTORS: IBN is a multifaceted financial news, content creation and publishing company utilized by both public and private companies to optimize investor awareness and recognition. For more information, please visit https://www.InvestorBrandNetwork.com
Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://IBN.fm/Disclaimer
The latest news and updates relating to QNTM are available in the company’s newsroom at https://ibn.fm/QNTM
Corporate Communications
IBN
Austin, Texas
www.InvestorBrandNetwork.com
512.354.7000 Office
[email protected]
Contact
IBN
www.InvestorBrandNetwork.com
[email protected]